JTJonathan J. Taliercio

Jonathan J. Taliercio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan J. Taliercio has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of Obesity and Body Composition and Hospitalization Risk with Infection in the CRIC Study

    by Yefei Yu, Bernard G. Jaar, Panduranga S. Rao, Zeenat Bhat, Hernan Rincon-Choles, Giselle Rodriguez de Sosa, Ana C. Ricardo, Jonathan Taliercio, Lucy Van Dyke, Jing Chen, et al.

    Key Points: Obesity is prevalent in people with CKD and may be a risk factor for developing serious infections. Among people with CKD, both obesity and underweight were significantly associated with the risk of infection. There was a strong association of obesity with skin infection, relative to other infection subtypes, which warrants further investigations. Background: People with CKD are at high risk of infection, potentially as a result of impaired immune function. Obesity is prevalent in people with CKD and may be a risk factor for developing serious infections. Methods: In 5499 participants of the Chronic Renal Insufficiency Cohort Study, we examined the association of measures of obesity and body composition with time to first hospitalization with infection, defined by hospital discharge records with a diagnostic code for major infections. Body mass index was categorized as underweight (2 ), normal weight (18.5–24.9), overweight (25.0–29.9), and class 1 (30.0–34.9); class 2 (35.0–39.9); and class 3 (≥40.0) obesity. Measures of body cell mass ( i.e ., phase angle) and tissue hydration status ( i.e ., vector length), assessed with bioelectrical impedance, were grouped into quartiles. We used multivariable Cox models to estimate adjusted hazard ratios (aHRs) of all-cause infection, as well as by infection subtypes. Results: During follow-up (median, 4.7 years), 2913 participants had hospitalization with infection. Compared with normal weight, class 3 obesity and underweight were both associated with a higher risk of all-cause infection (aHR, 1.35; 95% confidence interval [CI], 1.16 to 1.57 and 1.76; 95% CI, 1.06 to 2.93, respectively). Compared with the highest quartile, the lowest quartiles of phase angle and vector length were significantly associated with a higher risk of all-cause infection (aHR, 1.39; 95% CI, 1.22 to 1.57 and 1.17; 95% CI, 1.02 to 1.33, respectively). When the analysis was separately performed by infection subtypes, the association of obesity was particularly strong for skin and soft tissue infection (aHR, 1.98; 95% CI, 1.54 to 2.54), but not for others ( e.g ., aHR for lower respiratory tract infection, 0.96; 95% CI, 0.77 to 1.19), whereas underweight and shallow phase angle were broadly associated with the risk of infection across subtypes. Conclusions: Among people with CKD, both obesity and underweight were significantly associated with the risk of infection. The association of obesity with skin infection, relative to other infection subtypes, warrants further investigations.

  • Urine Biomarkers for Diabetic Kidney Disease Progression in Participants of the Chronic Renal Insufficiency Cohort Study

    by Sarah J. Schrauben, Xiaoming Zhang, Dawei Xie, Steven Coca, Jason H. Greenberg, Joachim H. Ix, Michael G. Shlipak, Chi-Yuan Hsu, Jonathan J. Taliercio, Chirag R. Parikh, et al.

    Key Points: Higher urine levels of kidney injury molecule-1 and monocyte chemoattractant protein-1 were associated with higher risk of CKD progression. Higher urine levels of EGF were associated with lower risk of CKD progression. Urine kidney injury molecule-1, monocyte chemoattractant protein-1, and EGF may noninvasively assess tubule and interstitial health in diabetes and identify those at higher risk of CKD progression. Background: Urine biomarkers of kidney tubular health and inflammation may provide a noninvasive way to identify individuals with diabetes at higher risk for CKD progression given that the extent of tubulointerstitial pathology is related to progression of diabetic kidney disease. Methods: We performed a case-cohort study among 898 participants in the Chronic Renal Insufficiency Cohort with diabetes and eGFR 2. Of these individuals, the subcohort (N=599) was randomly selected from participants with urine samples available 1 year or less after enrollment to assay for urine proteins. Cases were participants who developed CKD progression (incident ESKD, or eGFR decline of 40% or greater from baseline). The median follow-up was 7.35 years. We studied urinary biomarkers of tubulointerstitial inflammation (monocyte chemoattractant protein-1 [MCP-1]), proximal tubular injury (kidney injury molecule-1 [KIM-1]), tubular resorptive capacity (α1-microglobulin), and tubular synthetic capacity (EGF and uromodulin). Weighted Cox regression models related urine biomarkers, standardized to urine creatinine (Cr), with CKD progression and were adjusted for CKD risk factors, including eGFR, and urine albumin-to-creatinine ratio. Results: In fully adjusted models, higher urine KIM-1/Cr was associated with higher risk of CKD progression (hazard ratio [HR], 1.16 per two-fold higher; 95% confidence interval [CI], 1.05 to 1.29) and the highest quartiles of urine KIM-1/Cr and urine MCP-1/Cr, compared with the lowest quartile, were associated with higher risk of CKD progression (HR, 1.71; 95% CI, 1.15 to 2.55, and HR, 1.65; 95% CI, 1.10 to 2.47, respectively). Higher urine levels of EGF/Cr were associated with lower risk of CKD progression (HR, 0.81 per two-fold higher; 95% CI, 0.71 to 0.93), and the highest quartile of urine EGF/Cr, compared with lowest, associated with less CKD progression (HR, 0.57; 95% CI, 0.40 to 0.81). Conclusions: Urine MCP-1, KIM-1, and EGF may provide noninvasive ways to assess tubule and interstitial disease in diabetes and identify those at higher risk of CKD progression.


  • Defining Kidney Health Dimensions and Their Associations with Adverse Outcomes in Persons with Diabetes and CKD

    by Vanessa-Giselle Peschard, Rebecca Scherzer, Michelle M. Estrella, Mark J. Sarnak, Simon B. Ascher, James Lash, Joseph V. Bonventre, Jason H. Greenberg, Orlando M. Gutierrez, Jeffrey R. Schelling, et al.

    Key Points: We identified three kidney health dimensions using 17 urine and plasma biomarkers across two cohorts of persons with diabetes and CKD. Worse scores for tubule injury, tubule function, and systemic inflammation/filtration were associated with a higher risk of CKD progression and death. A multibiomarker approach could help capture tubulointerstitial health in persons with diabetes and CKD. Background: Individual kidney tubule biomarkers are associated with risks of CKD progression and mortality in persons with diabetes. Integrating multiple kidney biomarkers using a latent variable method of exploratory factor analysis could define distinct dimensions of kidney health and their associations with adverse outcomes. Methods: We conducted a factor analysis of 17 candidate urine and plasma biomarkers in 1256 participants with diabetes and eGFR 2 from the Chronic Renal Insufficiency Cohort (CRIC; N=701) and the REasons for Geographic And Racial Differences in Stroke (REGARDS; N=555) studies. We used Cox proportional hazards models to evaluate the associations of identified factors with CKD progression and mortality, adjusting for baseline clinical risk factors, eGFR, and albuminuria. Results: Three factor scores comprising ten biomarkers were identified: systemic inflammation and filtration (plasma TNF receptor-1 and TNF receptor-2, plasma soluble urokinase plasminogen activator receptor, and plasma symmetric dimethylarginine), tubular function (urine EGF, urine asymmetric dimethylarginine, and urine symmetric dimethylarginine), and tubular damage (urine α-1 microglobulin, urine kidney injury molecule-1, and urine monocyte chemoattractant protein-1). In CRIC, there were 244 incident ESKD events, 102 with ≥40% eGFR decline from baseline, and 259 deaths; in REGARDS, there were 121 incident ESKD events and 462 deaths. In CRIC, lower tubular function (hazard ratio per 1-SD, 0.36; 95% confidence interval, 0.25 to 0.52) and higher tubular damage (1.45; 1.18 to 1.78) scores were independently associated with higher CKD progression risk. Associations in REGARDS were weaker but directionally consistent (tubular function score [0.81; 0.47 to 1.39] and tubular damage score [1.12; 0.73 to 1.72]). Higher tubular damage (1.47; 1.15 to 1.87) scores were associated with higher mortality risk in CRIC, but not REGARDS (1.15; 0.96 to 1.38). Higher systemic inflammation and filtration factor scores were associated with higher mortality risk in both cohorts (CRIC: 1.35; 1.07 to 1.71; REGARDS: 1.41; 1.20 to 1.65). Conclusions: Three distinct kidney health dimensions were identified, and each associated with CKD progression and/or all-cause mortality in persons with diabetes and CKD.


  • Surrogate End Points in Apolipoprotein L1–Associated Kidney Disease

    by Alix T. Rosenberg, Carina Flaherty, Amanda H. Anderson, Lawrence J. Appel, Josef Coresh, Jiang He, James P. Lash, Celina Liu, Panduranga S. Rao, Jonathan Taliercio, et al.

    Key Points: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. Background: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 ( APOL1 )-associated kidney disease. Methods: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study ( N =3071), Chronic Renal Insufficiency Cohort ( N =998), and African American Study of Kidney Disease and Hypertension ( N =609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m 2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. Results: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. Conclusions: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 -associated kidney disease.


  • Factors Associated With Non-vaccination for Influenza Among Patients With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

    by Junichi Ishigami, Bernard G. Jaar, Jeanne B. Charleston, James P. Lash, Julia Brown, Jing Chen, Katherine T. Mills, Jonathan J. Taliercio, Sheru Kansal, Deidra C. Crews, et al.


  • Risk for Chronic Kidney Disease Progression After Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort Study

    by Anthony N. Muiru, Jesse Y. Hsu, Xiaoming Zhang, Lawrence J. Appel, Jing Chen, Debbie L. Cohen, Paul E. Drawz, Barry I. Freedman, Alan S. Go, Jiang He, et al.

    Prior studies associating acute kidney injury (AKI) with more rapid subsequent loss of kidney function had methodological limitations, including inadequate control for differences between patients who had AKI and those who did not. To determine whether AKI is independently associated with subsequent kidney function trajectory among patients with chronic kidney disease (CKD). Multicenter prospective cohort study. United States. Patients with CKD (n = 3150). Hospitalized AKI was defined by a 50% or greater increase in inpatient serum creatinine (SCr) level from nadir to peak. Kidney function trajectory was assessed using estimated glomerular filtration rate (eGFR) based on SCr level (eGFRcr) or cystatin C level (eGFRcys) measured at annual study visits. During a median follow-up of 3.9 years, 433 participants had at least 1 AKI episode. Most episodes (92%) had stage 1 or 2 severity. There were decreases in eGFRcr (-2.30 [95% CI, -3.70 to -0.86] mL/min/1.73 m2) and eGFRcys (-3.61 [CI, -6.39 to -0.82] mL/min/1.73 m2) after AKI. However, in fully adjusted models, the decreases were attenuated to -0.38 (CI, -1.35 to 0.59) mL/min/1.73 m2 for eGFRcr and -0.15 (CI, -2.16 to 1.86) mL/min/1.73 m2 for eGFRcys, and the CI bounds included the possibility of no effect. Estimates of changes in eGFR slope after AKI determined by either SCr level (0.04 [CI, -0.30 to 0.38] mL/min/1.73 m2 per year) or cystatin C level (-0.56 [CI, -1.28 to 0.17] mL/min/1.73 m2 per year) also had CI bounds that included the possibility of no effect. Few cases of severe AKI, no adjudication of AKI cause, and lack of information about nephrotoxic exposures after hospital discharge. After pre-AKI eGFR, proteinuria, and other covariables were accounted for, the association between mild to moderate AKI and worsening subsequent kidney function in patients with CKD was small. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.


  • Open Access

    IgA nephropathy

    by Jonathan J. Taliercio, Ali Mehdi

    Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis in the world. The etiology is unknown but a dysregulated T-cell immune response to viral, bacterial, and food antigens activating mucosal plasma cells to produce polymeric IgA has been proposed. No serological test exists to diagnosis IgAN. A definitive diagnosis requires kidney biopsy which is not always necessary. Kidney failure occurs in 20% to 40% of patients within 10 to 20 years.


  • Probing the Association between Acute Kidney Injury and Cardiovascular Outcomes

    by Ian E. McCoy, Jesse Y. Hsu, Xiaoming Zhang, Clarissa J. Diamantidis, Jonathan Taliercio, Alan S. Go, Kathleen D. Liu, Paul Drawz, Anand Srivastava, Edward J. Horwitz, et al.

    Background: Patients hospitalized with AKI have higher subsequent risks of heart failure, atherosclerotic cardiovascular events, and mortality than their counterparts without AKI, but these higher risks may be due to differences in prehospitalization patient characteristics, including the baseline level of estimated glomerular filtration rate (eGFR), the rate of prior eGFR decline, and the proteinuria level, rather than AKI itself. Methods: Among 2177 adult participants in the Chronic Renal Insufficiency Cohort study who were hospitalized in 2013–2019, we compared subsequent risks of heart failure, atherosclerotic cardiovascular events, and mortality between those with serum creatinine–based AKI (495 patients) and those without AKI (1682 patients). We report both crude associations and associations sequentially adjusted for prehospitalization characteristics including eGFR, eGFR slope, and urine protein-creatinine ratio (UPCR). Results: Compared with patients hospitalized without AKI, those with hospitalized AKI had lower eGFR prehospitalization (42 versus 49 ml/min per 1.73 m2), faster chronic loss of eGFR prehospitalization (−0.84 versus −0.51 ml/min per 1.73 m2 per year), and more proteinuria prehospitalization (UPCR 0.28 versus 0.16 g/g); they also had higher prehospitalization systolic BP (130 versus 127 mm Hg; P < 0.01 for all comparisons). Adjustment for prehospitalization patient characteristics attenuated associations between AKI and all three outcomes, but AKI remained an independent risk factor. Attenuation of risk was similar after adjustment for absolute eGFR, eGFR slope, or proteinuria, individually or in combination. Conclusions: Prehospitalization variables including eGFR, eGFR slope, and proteinuria confounded associations between AKI and adverse cardiovascular outcomes, but these associations remained significant after adjusting for prehospitalization variables.


  • Open Access

    Resistant hypertension: A stepwise approach

    by Jordana Yahr, George Thomas, Juan Calle, Jonathan J. Taliercio

    Resistant hypertension can be challenging to manage, but a stepwise approach to diagnosis, evaluation, and treatment can lead to better blood pressure control. In this article, we review the definition and prevalence of resistant hypertension and its diagnostic workup and management, including lifestyle modifications, drugs, and experimental interventional therapies.


  • Open Access

    Dysnatremias, Mortality, and Kidney Failure in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

    by Mohamed Hassanein, Susana Arrigain, Jesse D. Schold, Georges N. Nakhoul, Sankar D. Navaneethan, Ali Mehdi, Arjun Sekar, Jad Tabbara, Jonathan J. Taliercio